« Return to News | R&D Trends | Drug Sponsors

ViroPharma contracts Recipharm to manufacture Plenadren

Monday, March 19, 2012 09:56 AM

Recipharm, the international contract pharmaceutical development and manufacturing organization, has been contracted by ViroPharma to complete commercial scale-up manufacture of Plenadren (hydrocortisone), used for the treatment of adrenal insufficiency in adults.

In addition, ViroPharma is investing in new equipment for Recipharm to increase the manufacturing capacity for Plenadren to support commercial product launches across Europe.

The new agreement follows the completion of Recipharm’s initial scale-up contract with DuoCort Pharma—recently acquired by ViroPharma following Plenadren’s receipt of European marketing authorization and confirmation of orphan drug designation.

Additionally, Recipharm will be able to use the new equipment for other projects, with ViroPharma retaining its status as highest priority customer.

Helene Fehrm, general manager of Recipharm Stockholm, said, “This investment and the work we are doing for ViroPharma will give us further valuable experience in tablet manufacturing with API in the coating—a unique advantage over conventional approaches—both for Plenadren itself and other customers moving forwards.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.